Wire · opportunities
FDA accepts Nicox's NDA for IOP-lowering glaucoma drop
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
The FDA has accepted the new drug application for Nicox's glaucoma treatment K-911, which combines nitric oxide and a prostaglandin analog to lower intraocular pressure. The standard 10-month review sets a Prescription Drug User Fee Act (PDUFA) action date of April 30, 2027, with a potential US commercial launch in the second half of 2027.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Your window to enter the US glaucoma treatment market opens with Nicox’s novel IOP-lowering drug nearing FDA review. Prepare to engage buyers or partners who will seek alternatives if this combination therapy captures superior clinical outcomes.
◆ Coverage
1 source · 31 Aug 2026
◆ Related on Wire
◆ Topics